Adicet Bio (NASDAQ:ACET – Get Free Report) and Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.
Profitability
This table compares Adicet Bio and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adicet Bio | N/A | -80.35% | -65.44% |
| Acumen Pharmaceuticals | N/A | -123.07% | -79.41% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Adicet Bio and Acumen Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adicet Bio | 1 | 1 | 5 | 1 | 2.75 |
| Acumen Pharmaceuticals | 1 | 0 | 3 | 0 | 2.50 |
Valuation and Earnings
This table compares Adicet Bio and Acumen Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adicet Bio | N/A | N/A | -$116.80 million | ($14.90) | -0.56 |
| Acumen Pharmaceuticals | N/A | N/A | -$121.33 million | ($1.86) | -1.35 |
Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Adicet Bio has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
Insider & Institutional Ownership
83.9% of Adicet Bio shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 3.4% of Adicet Bio shares are owned by company insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Adicet Bio beats Acumen Pharmaceuticals on 10 of the 12 factors compared between the two stocks.
About Adicet Bio
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.
